gsk2879552
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2014 (NCT02034123)
Timeline
Indications
Mechanism of action
KDM1A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)c1ccc(CN2CCC(CN[C@@H]3C[C@H]3c3ccccc3)CC2)cc1- Mol. weight
- 364.49 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3786182 ↗
Also known as
- gsk2879552
- gsk2879552
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02929498 | Phase 2 | Jul 14, 2017 | GlaxoSmithKline, Parexel |
| NCT02177812 | Phase 1 | Aug 1, 2014 | GlaxoSmithKline |
| NCT02034123 | Phase 1 | Feb 1, 2014 | GlaxoSmithKline |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 3 | 3 | 2 | 2014 |
| Parexel | For profit | 1 | 0 | 1 | 2017 |
2 organizations
Page 1 / 1